middle.news
Rhythm Biosciences Strengthens Balance Sheet and Expands ColoSTAT® Commercial Footprint
8:33am on Thursday 30th of July, 2026 AEST
•
Healthcare
Read Story
Rhythm Biosciences Strengthens Balance Sheet and Expands ColoSTAT® Commercial Footprint
8:33am on Thursday 30th of July, 2026 AEST
Key Points
Underwriting of $5.2m RHYO options strengthens cash reserves
ColoSTAT® test volumes and collection centres expanded nationally
ColoSTAT® Access Program grows to 16 clinicians boosting real-world evidence
Independent analytical evaluation of ColoSTAT® progressing in UK
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Rhythm Biosciences (ASX:RHY)
OPEN ARTICLE